PetCaseFinder

Peer-reviewed veterinary case report

Ultrasound and cytology predict spread in high-risk dog mast cell

By Book, Alison P et al.·Published in Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association·2011·Department of Veterinary Clinical Medicine, United States·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Correlation of ultrasound findings, liver and spleen cytology, and prognosis in the clinical staging of high metastatic risk canine mast cell tumors.

Species:
dog
Mast cell tumour (MCT)Stomach & digestionDogs

Plain-English summary

A group of dogs with aggressive mast cell tumors (a type of skin cancer) underwent treatment with chemotherapy and had their spleens and livers checked for cancer spread using ultrasound and cytology (cell analysis). Out of 19 dogs, 7 showed signs of cancer in their spleens or livers, but the ultrasound was not very effective in detecting this, missing many cases. Dogs with cancer spread to these organs had a much shorter survival time compared to those without. The study suggests that checking the spleen with a needle sample should be done even if the ultrasound looks normal, as it can provide important information about the dog's prognosis.

People also search for: dog mast cell tumor treatment · dog cancer spread to liver · ultrasound for dog cancer detection

Abstract

Cytologic sampling of the ultrasonographically normal spleen and liver is not implemented routinely in the clinical staging of canine cutaneous mast cell tumors and normal ultrasound findings are often accepted as sufficient evidence for ruling out splenic or liver metastasis. Our objective was to define the specificity and sensitivity of ultrasound findings for diagnosis of mast cell infiltration when verified with cytologic evaluation, and to define the prognostic role of cytologic evaluation of liver and splenic aspirates. Dogs with a diagnosis of clinically aggressive grade II, or grade III mast cell tumor treated with a combination vinblastine/CCNU chemotherapy protocol, were selected retrospectively based on availability of cytologic evaluation of spleen plus or minus liver for staging. Out of 19 dogs, 10 dogs had a grade II tumor and nine a grade III tumor. Seven dogs had mast cell infiltration of the spleen, liver, or both. The sensitivity of ultrasound for detecting mast cell infiltration was 43% for the spleen and 0% for the liver. Dogs with positive cytologic evidence of mast cell infiltration to spleen, liver, or both had significantly shorter survival (100 vs. 291 days) than dogs without evidence of mast cell infiltration (P<0.0001). Routine splenic aspiration should be performed regardless of ultrasonographic appearance in dogs with a clinically aggressive mast cell tumor.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21689203/